Navigation Links
InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
Date:9/17/2009

BRISBANE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).

The database, which includes DNA from approximately 1,500 IPF patients, is the largest in the world and offers researchers an opportunity to gain important new insights regarding the pathogenesis of this devastating disease. This announcement comes during the 2009 National Pulmonary Fibrosis (PF) Awareness Week, which is taking place this year September 14 - 21, 2009.

"This is an ideal partnership that will enhance our chances to make breakthroughs in understanding the causes of this disease, the optimal diagnostic strategies and the best prognosticators for patient outcomes," said David Schwartz, MD, the principal investigator of this research.

"We are pleased to be able to partner with National Jewish Health, one of the world's leading institutions in pulmonary medicine, in this important pursuit to better understand the role that genetic factors may play in the development of IPF, a disease that claims approximately 40,000 lives per year," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. "With nearly a decade of experience in IPF research and development, we are committed toward advancing care for patients with this uniformly fatal disease who currently hav
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... The new , Healthcare and Life ... today on PharmaBoardroom.com for free download , ... the Spanish economy in 2009, and the austerity measures that ... pragmatic in times of trouble. "Despite the crisis, ... European market, and the general conditions to invest are favorable ...
(Date:9/18/2014)... 18, 2014 A novel robotic system ... scanner is currently being tested as part of a ... in Boston with the aim of determining if the ... prostate cancer biopsies faster, more accurate, less costly, and ... has the potential to deliver prostate cancer therapies with ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Kultevat obtains license of gene switch technology 2
... suffering from uterine fibroids, a debilitating condition that affects ... soon have reason for hope.  Halt Medical, a biomedical ... developing a minimally invasive procedure for treating the condition. ... Latin America at the NIH Global Fibroid Congress.   ...
... One of the requirements to keep trends in computer technology ... energy-efficient is faster writing and processing of data. In ... physicists at the Technische Universitaet Muenchen (TUM) and the Universitaet ... a solution. TUM physicists set a lattice of magnetic vortices ...
... 17, 2010 InterMune, Inc. (Nasdaq: ITMN ... to prepare for the commercialization of Esbriet™ (pirfenidone) in ... a positive CHMP opinion that is now awaiting ratification ... Chief Executive Officer and President of InterMune, said, "We ...
Cached Biology Technology:Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress 2Electric current moves magnetic vortices 2InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 2InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 3InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 4InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 5InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 6
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... robotic system that can operate inside the bore of ... of a biomedical research partnership program at Brigham and ... if the robot, in conjunction with real-time MRI images, ... costly, and less discomforting for the patient. The novel ... therapies with greater precision. , Developed by a team ...
(Date:9/18/2014)... MADISON, Wis. No matter how many times ... as social, communicating creatures. , But by ... single-celled organisms radically alter their behavior to suit ... many of them are present, and act accordingly. ... the millions, it may change from innocuous to ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... that BioMed Central's Open Access journals are high quality ... Central have again received impact factors that compare well ... five titles in the top five of their specialty. ... they are respected by researchers, and are fast becoming ...
... Impressive impact factors prove that BioMed Central's Open Access ... Journals published by BioMed Central have again received impact ... was announced today, with five titles in the top ... these journals affirm that they are respected by researchers, ...
... in repairing lung damage, according to a team of scientists ... repair process in lung transplant patients. , Reporting in today's ... of The University of Texas Medical School at Houston, and ... that less than 1 percent of a certain type of ...
Cached Biology News:'Bionic' arm gives amputee sense of touch 2Open Access journals get impressive impact factors 2Circulating stem cells play small role in lung repair 2Circulating stem cells play small role in lung repair 3
MOUSE ANTI RAT RT1Ac Immunogen: PHA activated rat lymphocytes...
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
Biology Products: